Clinical Cancer Research SCISCIE

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.

Clinical Cancer Research 发表创新的临床和转化癌症研究，将实验室和诊所联系起来。该杂志对评估新疗法的临床试验特别感兴趣，伴随着药理学研究，以及预测治疗反应或耐药性的分子改变或生物标志物。该杂志还优先考虑对可能导致临床试验的新药和分子靶向药物的实验室和动物研究，以及对肿瘤发生、恶性表型进展和转移性疾病的靶向机制的研究。

感兴趣的具体领域包括靶向治疗的临床和转化研究；药物敏感性和耐药性机制；药物遗传学和药物基因组学；个性化医疗；生物信息学和生物统计学的新应用；免疫治疗和临床免疫学；基因治疗;放射生物学和放射肿瘤学；人类肿瘤的大规模分子表征；诊断生物标志物；创新成像和其他可能适用于临床研究的新方法；临床遗传学；和检测微小疾病。

该刊已被国际权威数据库SCI、SCIE收录，是国际顶级期刊。该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-肿瘤学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2022年影响因子为11.5，平均审稿速度为约2.1月，近三年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。